Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 13, 2009, Pages 3511-3516

  Takahashi, Toshiyuki ^a   Haga, Yuji ^a   Sakamoto, Toshihiro ^a   Moriya, Minoru ^a   Okamoto, Osamu ^a   Nonoshita, Katsumasa ^a   Shibata, Takunobu ^a   Suga, Takuya ^a   Takahashi, Hirobumi ^a   Hirohashi, Tomoko ^a   Sakuraba, Aya ^a   Gomori, Akira ^a   Iwaasa, Hisashi ^a   Ohe, Tomoyuki ^a   Ishihara, Akane ^a   Ishii, Yasuyuki ^a   Kanatani, Akio ^a   Fukami, Takehiro ^a  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Antagonist; Neuropeptide Y; NPY; Obesity

Indexed keywords

NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NEUROPEPTIDE Y5 RECEPTOR; PIPERIDINE DERIVATIVE; SPIRO[3 OXOISOBENZOFURANE 1(3H),4' PIPERIDINE] DERIVATIVE; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; FOOD INTAKE; IC 50; MOUSE; NEUROMODULATION; NONHUMAN; OBESITY; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-OBESITY AGENTS; EATING; HUMANS; MICE; PIPERIDINES; RATS; RECEPTORS, NEUROPEPTIDE Y; SPIRO COMPOUNDS; UREA; WEIGHT LOSS;

MUS; RATTUS;

EID: 66349107638     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.05.013     Document Type: Article

References (48)

1. Tatemoto K., and Mutt V. Nature 285 (1980) 417
2. Tatemoto K., Carlquist M., and Mutt V. Nature 296 (1982) 659
3. Clark J.T., Kalra P.S., Crowley W.R., and Kalra S.P. Endocrinology 115 (1984) 427
4. Mccarthy H.D., Mckibbin P.E., Holloway B., Mayers R., and Williams G. Life Sci. 49 (1991) 1491
5. Eva C., Oberto A., Sprengel R., and Genazzani E. FEBS Lett. 314 (1992) 285
6. Herzog H., Hort Y.J., Ball H.J., Hayes G., Shine J., and Selbie L.A. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 5794
7. Krause J., Eva C., Seeburg P.H., and Sprengel R. Mol. Pharmacol. 41 (1992) 817
8. Larhammar D., Blomqvist A.G., Yee F., Jazin E., Yoo H.Y., and Wahlestedt C. J. Biol. Chem. 267 (1992) 10935
9. Bard J.A., Walker M.W., Branchek T.A., and Weinshank R.L. J. Biol. Chem. 270 (1995) 26762
10. Gerald C., Walker M.W., Vaysse P.J.J., He C.G., Branchek T.A., and Weinshank R.L. J. Biol. Chem. 270 (1995) 26758
11. Lundell I., Blomqvist A.G., Berglund M.M., Schober D.A., Johnson D., Statnick M.A., Gadski R.A., Gehlert D.R., and Larhammar D. J. Biol. Chem. 270 (1995) 29123
12. Rose P.M., Fernandes P., Lynch J.S., Frazier S.T., Fisher S.M., Kodukula K., Kienzle B., and Seethala R. J. Biol. Chem. 270 (1995) 22661
13. Gehlert D.R., Beavers L.S., Johnson D., Gackenheimer S.L., Schober D.A., and Gadski R.A. Mol. Pharmacol. 49 (1996) 224
14. Gerald C., Walker M.W., Criscione L., Gustafson E.L., BatzlHartmann C., Smith K.E., Vaysse P., Durkin M.M., Laz T.M., Linemeyer D.L., Schaffhauser A.O., Whitebread S., Hofbauer K.G., Taber R.I., Branchek T.A., and Weinshank R.L. Nature 382 (1996) 168
15. Gregor P., Millham M.L., Feng Y., Decarr L.B., McCaleb M.L., and Cornfield L.J. FEBS Lett. 381 (1996) 58
16. Gregor P., Feng Y., Decarr L.B., Cornfield L.J., and McCaleb M.L. J. Biol. Chem. 271 (1996) 27776
17. Hu Y.H., Bloomquist B.T., Cornfield L.J., Decarr L.B., FloresRiveros J.R., Friedman L., Jiang P.L., LewisHiggins L., Sadlowski Y., Schaefer J., Velazquez N., and McCaleb M.L. J. Biol. Chem. 271 (1996) 26315
18. Matsumoto M., Nomura T., Momose K., Ikeda Y., Kondou Y., Akiho H., Togami J., Kimura Y., Okada M., and Yamaguchi T. J. Biol. Chem. 271 (1996) 27217
19. Weinberg D.H., Sirinathsinghji D.J.S., Tan C.P., Shiao L.L., Morin N., Rigby M.R., Heavens R.H., Rapoport D.R., Bayne M.L., Cascieri M.A., Strader C.D., Linemeyer D.L., and MacNeil D.J. J. Biol. Chem. 271 (1996) 16435
20. Daniels A.J., Matthews J.E., Slepetis R.J., Jansen M., Viveros O.H., Tadepalli A., Harrington W., Heyer D., Landavazo A., Leban J.J., and Spaltenstein A. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 9067
21. Kanatani A., Ishihara A., Asahi S., Tanaka T., Ozaki S., and Ihara M. Endocrinology 137 (1996) 3177
22. Hipskind P.A., Lobb K.L., Nixon J.A., Britton T.C., Bruns R.F., Catlow J., DieckmanMcGinty D.K., Gackenheimer S.L., Gitter B.D., Iyengar S., Schober D.A., Simmons R.M.A., Swanson S., Zarrinmayeh H., Zimmerman D.M., and Gehlert D.R. J. Med. Chem. 40 (1997) 3712
23. Kanatani A., Ito J., Ishihara A., Iwaasa H., Fukuroda T., Fukami T., MacNeil D.J., Van der Ploeg L.H.T., and Ihara M. Regul. Pept. 75-6 (1998) 409
24. Kask A., Rago L., and Harro J. Br. J. Pharmacol. 124 (1998) 1507
25. Marsh D.J., Hollopeter G., Kafer K.E., and Palmiter R.D. Nat. Med. 4 (1998) 718
26. Pedrazzini T., Seydoux J., Kunstner P., Aubert J.F., Grouzmann E., Beermann F., and Brunner H.R. Nat. Med. 4 (1998) 722
27. Wieland H.A., Engel W., Eberlein W., Rudolf K., and Doods H.N. Br. J. Pharmacol. 125 (1998) 549
28. Inui A. Trends Pharmacol. Sci. 20 (1999) 43
29. Kanatani A., Kanno T., Ishihara A., Hata M., Sakuraba A., Tanaka T., Tsuchiya Y., Mase T., Fukuroda T., Fukami T., and Ihara M. Biochem. Biophys. Res. Commun. 266 (1999) 88
30. Kanatani A., Mashiko S., Murai N., Sugimoto N., Ito J., Fukuroda T., Fukami T., Morin N., MacNeil D.J., Van der Ploeg L.H.T., Saga Y., Nishimura S., and Ihara M. Endocrinology 141 (2000) 1011
31. Kanatani A., Hata M., Mashiko S., Ishihara A., Okamoto O., Haga Y., Ohe T., Kanno T., Murai N., Ishii Y., Fukuroda T., Fukami T., and Ihara M. Mol. Pharmacol. 59 (2001) 501
32. Poindexter G.S., Bruce M.A., LeBoulluec K.L., Monkovic I., Martin S.W., Parker E.M., Iben L.G., McGovern R.T., Ortiz A.A., Stanley J.A., Mattson G.K., Kozlowski M., Arcuri M., and Antal-Zimanyi I. Bioorg. Med. Chem. Lett. 12 (2002) 379
33. Sakamoto T., Moriya M., Haga Y., Takahashi T., Shibata T., Okamoto O., Nonoshita K., Kitazawa H., Hidaka M., Gomori A., Iwaasa H., Ishihara A., Kanatani A., Fukami T., Gao Y.D., MacNeil D.J., and Yang L. Bioorg. Med. Chem. Lett. 19 (2009) 1564
34. Chambers M.S., Baker R., Billington D.C., Knight A.K., Middlemiss D.N., and Wong E.H.F. J. Med. Chem. 35 (1992) 2033
35. Evans B.E., Leighton J.L., Rittle K.E., Gilbert K.F., Lundell G.F., Gould N.P., Hobbs D.W., Dipardo R.M., Veber D.F., Pettibone D.J., Clineschmidt B.V., Anderson P.S., and Freidinger R.M. J. Med. Chem. 35 (1992) 3919
36. Patchett A.A., Nargund R.P., Tata J.R., Chen M.H., Barakat K.J., Johnston D.B.R., Cheng K., Chan W.W.S., Butler B., Hickey G., Jacks T., Schleim K., Pong S.S., Chaung L.Y.P., Chen H.Y., Frazier E., Leung K.H., Chiu S.H.L., and Smith R.G. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 7001
37. Chen M.H., Steiner M.G., Patchett A.A., Cheng K., Wei L.T., Chan W.W.S., Butler B., Jacks T.M., and Smith R.G. Bioorg. Med. Chem. Lett. 6 (1996) 2163
38. Barakat K.J., Cheng K., Chan W.W.S., Butler B.S., Jacks T.M., Schleim K.D., Hora D.F., Hickey G.J., Smith R.G., Patchett A.A., and Nargund R.P. Bioorg. Med. Chem. Lett. 8 (1998) 1431
39. Evans B.E., Rittle K.E., Bock M.G., Dipardo R.M., Freidinger R.M., Whitter W.L., Lundell G.F., Veber D.F., Anderson P.S., Chang R.S.L., Lotti V.J., Cerino D.J., Chen T.B., Kling P.J., Kunkel K.A., Springer J.P., and Hirshfield J. J. Med. Chem. 31 (1988) 2235
40. According to the Merck Index, 14th edition, potential symptoms of overexposure are headache, dizziness; lethargy, dyspnea; ataxia, weakness; methemoglobinemia; urinary burning; acute hemorrhagic cystitis. See NIOSH Pocket Guide to Chemical Hazards (DHHS/NIOSH 97-140, 1997) p 14. This substance is listed as a known human carcinogen: Report on Carcinogens, Eleventh Edition (PB2005-104914, 2004) p III-13.
41. 125I]PYY binding to human recombinant Y5 receptors in LMtk- cells; see Ref. 43.
42. Compound 5g at 10 μM showed 15% or 46% inhibition without or with 45 min preincubation in a CYP3A4 inhibition assay.
43. Kanatani A., Ishihara A., Iwaasa H., Nakamura K., Okamoto O., Hidaka M., Ito J., Fukuroda T., MacNeil D.J., Van der Ploeg L.H.T., Ishii Y., Okabe T., Fukami T., and Ihara M. Biochem. Biophys. Res. Commun. 272 (2000) 169
44. 34NPY (1 ug, dissolved in artificial cerebrospinal fluid) was intracerebroventricularly injected and food intake was monitored for 2 h.
45. Sato N., Jitsuoka M., Shibata T., Hirohashi T., Nonoshita K., Moriya M., Haga Y., Sakuraba A., Ando M., Ohe T., Iwaasa H., Gomori A., Ishihara A., Kanatani A., and Fukami T. J. Med. Chem. 51 (2008) 4765
46. 4, 118 mL of 200 mM NaOH and water were mixed in a measuring flask (1000 mL).
47. Mashiko S., Ishihara A., Iwaasa H., Moriya R., Kitazawa H., Mitobe Y., Ito J., Gomori A., Matsushita H., Takahashi T., MacNeil D.J., Van der Ploeg L.H.T., Fukami T., and Kanatani A. Obesity 16 (2008) 1510
48. Ishihara A., Kanatani A., Mashiko S., Tanaka T., Hidaka M., Gomori A., Iwaasa H., Murai N., Egashira S., Murai T., Mitobe Y., Matsushita H., Okamoto O., Sato N., Jitsuoka M., Fukuroda T., Ohe T., Guan X.M., MacNeil D.J., Van der Ploegn L.H.T., Nishikibe M., Ishii Y., Ihara M., and Fukami T. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 7154